The Y181C Substitution in 3′-Azido-3′-deoxythymidine-resistant Human Immunodeficiency Virus, Type 1, Reverse Transcriptase Suppresses the ATP-mediated Repair of the 3′-Azido-3′-deoxythymidine 5′-Monophosphate-terminated Primer
Open Access
- 1 October 2003
- journal article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 278 (42), 40464-40472
- https://doi.org/10.1074/jbc.m302928200
Abstract
No abstract availableKeywords
This publication has 62 references indexed in Scilit:
- A Mechanism of AZT ResistanceMolecular Cell, 1999
- DiscussionBiochemical Pharmacology, 1999
- Phenotypic Mechanism of HIV-1 Resistance to 3‘-Azido-3‘-deoxythymidine (AZT): Increased Polymerization Processivity and Enhanced Sensitivity to Pyrophosphate of the Mutant Viral Reverse TranscriptaseBiochemistry, 1998
- Enhanced Binding of Azidothymidine-resistant Human Immunodeficiency Virus 1 Reverse Transcriptase to the 3′-Azido-3′-deoxythymidine 5′-Monophosphate-terminated PrimerJournal of Biological Chemistry, 1998
- An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk] [1,4]benzodiazepin-2 (1H)-one and -thione derivatives.Proceedings of the National Academy of Sciences, 1991
- Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivativesNature, 1990
- Computer analysis of retroviral pol genes: assignment of enzymatic functions to specific sequences and homologies with nonviral enzymes.Proceedings of the National Academy of Sciences, 1986
- Characterization of Highly Immunogenic p66/p51 as the Reverse Transcriptase of HTLV-III/LAVScience, 1986
- 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.Proceedings of the National Academy of Sciences, 1985
- A detailed model of reverse transcription and tests of crucial aspectsCell, 1979